Exelixis 报告称，在更广泛的患者可及性和新用途的推动下，2025 年第三季度肿瘤药物的收入强劲增长，同时推进了罕见和实体瘤治疗的试验。 Exelixis reported strong revenue growth in Q3 2025 from oncology drugs, driven by broader patient access and new uses, while advancing trials for rare and solid tumor treatments.

Exelixs报告了2025年第三季度的成果,指出其肿瘤治疗的收入继续增长,其驱动因素是患者获得治疗的机会扩大和新的迹象。 Exelixis reported third-quarter 2025 results, noting continued growth in revenue from its oncology therapies driven by expanded patient access and new indications. 该公司分享了针对固体肿瘤和罕见癌症的调查药物临床试验的进展,但没有透露具体数据。 The company shared progress in clinical trials for investigational drugs targeting solid tumors and rare cancers, without disclosing specific data. Exexexexexix强调精密医学、全球扩张和战略伙伴关系方面的进展,同时由于市场和偿还方面的挑战,保持了谨慎的近期财政前景。 Exelixis emphasized advancements in precision medicine, global expansion, and strategic partnerships, while maintaining a cautious near-term financial outlook due to market and reimbursement challenges. 该公司重申其对研发和长期价值的承诺,没有宣布任何领导或结构变革。 The company reaffirmed its commitment to R&D and long-term value, with no leadership or structural changes announced.